文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA PET/CT后联合MRI的整合诊断策略提高前列腺癌诊断准确性

The integrated diagnostic strategy of performing PSMA PET/CT followed by MRI improves the diagnostic accuracy of prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-06

本研究回顾性分析181例疑似前列腺癌患者的前瞻性数据集,评估在Al18F-NOTA-PSMA-617 PET/CT的PRIMARY评分基础上,对评分3或4的患者追加bpMRI进行诊断细化的价值。结果显示,新诊断路径特异性从58.7%显著提高至79.3%(p<0.001),敏感性保持可比(96.6% vs 93.3%,p=0.25),仅少量低病理分级患者被额外漏诊。

要点

  • PRIMARY评分3或4患者追加bpMRI可将特异性从58.7%提高至79.3%。
  • 新路径敏感性93.3%与PRIMARY评分96.6%保持可比(p=0.25)。
  • 细化后转为阴性的22例中仅3例为csPCa,均为ISUP 2。

核心结论

  • 对PRIMARY评分为3或4的患者追加bpMRI可提高csPCa诊断特异性,同时保持敏感性可比,仅少量低病理分级患者被额外漏诊。

研究设计与样本

  • 回顾性分析前瞻性收集的数据集,疑似前列腺癌患者3个月内完成Al18F-NOTA-PSMA-617 PET/CT与bpMRI检查。
  • PRIMARY评分由两名核医学医师独立盲法评估,评分≥3归为恶性,评分3或4者进一步通过bpMRI细化诊断。
  • 以3个月内获取的病理结果为参考,计算敏感性、特异性、PPV和NPV。

主要发现

  • 共纳入181例患者,PRIMARY评分1-5的csPCa发生率分别为0(0/18)、7.7%(3/39)、15.4%(2/13)、55.0%(22/40)和87.3%(62/71)。
  • PRIMARY评分的敏感性、特异性、PPV和NPV分别为96.6%、58.7%、69.4%和94.7%。
  • 经bpMRI细化后,22例患者转为阴性组,其中仅3例为csPCa且均为ISUP 2。
  • 新诊断路径的敏感性、特异性、PPV和NPV分别为93.3%、79.3%、81.4%和92.4%。
  • 特异性显著提高(p < 0.001),敏感性保持相同(p = 0.25)。

关键数值与推荐

  • PRIMARY评分≥3分类为恶性。
  • PRIMARY评分1-5对应的csPCa发生率分别为0(0/18)、7.7%(3/39)、15.4%(2/13)、55.0%(22/40)、87.3%(62/71)。
  • PRIMARY评分敏感性96.6%、特异性58.7%、PPV 69.4%、NPV 94.7%。
  • 新诊断路径敏感性93.3%、特异性79.3%、PPV 81.4%、NPV 92.4%。

临床怎么用

  • 对疑似前列腺癌患者先行Al18F-NOTA-PSMA-617 PET/CT评估PRIMARY评分,评分3或4者追加bpMRI细化诊断,可提高csPCa诊断特异性并减少不必要活检。

局限性

  • 本研究为回顾性分析,虽基于前瞻性收集的数据集,仍可能存在选择偏倚。
  • 原文未报告研究的具体时间范围、中心数量及bpMRI判读的一致性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PRIMARY score uses intraprostatic uptake patterns and uptake intensity of PSMA and has good performance in identifying clinically significant prostate cancer (csPCa). However, diagnostic accuracy is not satisfying in patients with PRIMARY score of 3 and 4, which may account for the relatively low specificity of PRIMARY score. MRI may improve the accuracy of PRIMARY score. This study aims to investigate the added value of bpMRI to Al18F-NOTA-PSMA-617 PET/CT in diagnosis of csPCa. METHODS: This is a retrospective analysis of a prospectively collected dataset. Al18F-NOTA-PSMA-617 PET/CT and bpMRI were performed within 3 months in patients with suspected PCa. PRIMARY scores were evaluated in a blinded manner by two nuclear medicine physicians independently. Lesions with PRIMARY score of ≥ 3 were classified as malignant. Besides, lesions with PRIMARY score 3 or 4 underwent further diagnostic refinement via bpMRI. Pathology was obtained within three months after completing bpMRI and PSMA PET/CT. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. RESULTS: 181 patients were included in this analysis. The incidence of csPCa in PRIMARY score 1-5 is 0 (0/18), 7.7% (3/39), 15.4% (2/13), 55.0% (22/40) and 87.3% (62/71). The sensitivity, specificity, PPV and NPV of PRIMARY score are 96.6%, 58.7%, 69.4% and 94.7%. After diagnostic refinement via bpMRI in patients with PRIMARY score 3 or 4, 22 patients were changed to the negative group. Only 3 of 22 patients, all with ISUP 2, had csPCa. The sensitivity, specificity, PPV, and NPV of the new diagnostic pathway were 93.3%, 79.3%, 81.4% and 92.4%. The specificity increased significantly (p < 0.001) while the sensitivity remained the same (p = 0.25). CONCLUSION: Addition of bpMRI in patients with PRIMARY scores of 3 or 4 improved specificity for diagnosing csPCa while maintaining comparable sensitivity levels. Only a small proportion of patients were additionally missed, all of whom had low pathological grades. The novel diagnostic strategy represents an effective, safe, and efficient approach to identify csPCa with significant clinical application value.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ma J, Wang C, Wang M, et al. The integrated diagnostic strategy of performing PSMA PET/CT followed by MRI improves the diagnostic accuracy of prostate cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 41491032. doi:10.1007/s00259-025-07731-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。